ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center

Los Angeles, July 24, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA. Dana-Farber Cancer Institute is a world-renowned research and treatment center for cancer and other life-threatening diseases based in Boston, Massachusetts, a principal teaching affiliate of Harvard Medical School.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH